Evidence map›Paper›PMID 37463810›Full record

ArticleBMJ open2023

Clinical course and outcomes in adults with co-occurring hypertrophic cardiomyopathy and hypertension: a scoping review protocol.

Milla Arabadjian, Barnaby Nicolas, Sophie Montgomery, Mitchell Pleasure, Maxine Collins, Maria Reuter, Daniele Massera, Daichi Shimbo, Mark Sherrid

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Milla ArabadjianCenter for Population and Health Services Research, Department of Foundations of Medicine, NYU Long Island School of Medicine, Mineola, New York, USA milla.arabadjian@nyulangone.org.ORCID 0000-0003-3307-1406
Barnaby NicolasDepartment of Foundations of Medicine, NYU Long Island School of Medicine, Mineola, New York, USA.ORCID 0000-0003-0999-9415
Sophie MontgomeryNYU Grossman School of Medicine, New York City, New York, USA.
Mitchell PleasureNYU Grossman School of Medicine, New York City, New York, USA.
Maxine CollinsUniversity of Connecticut School of Nursing, Storrs, Connecticut, USA.
Maria ReuterHypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York City, New York, USA.
Daniele MasseraHypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York City, New York, USA.
Daichi ShimboDivision of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Mark SherridHypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York City, New York, USA.
NYU Langone Health · USLong Island University · USNew York University · USColumbia University Irving Medical Center · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHypertension affects 40%-60% of adults with hypertrophic cardiomyopathy (HCM), the most common inherited cardiac condition. It can be a diagnostic confounder for HCM, contributing to delayed diagnosis. Clinically, treatment of co-occurring hypertension and HCM poses challenges as first-line and second-line antihypertensive medications are often contraindicated in HCM. The clinical course in adults with hypertension and HCM is also not well understood, and studies examining patient outcomes in this population are equivocal. In this paper, we aim to outline the protocol of a scoping review, a type of literature review, to systematically synthesise existing knowledge on adults with co-occurring HCM and hypertension, highlighting knowledge and evidence gaps, and identifying future research directions to optimise outcomes in this population. METHODS AND ANALYSIS: This review is guided by Arksey and O'Malley's conceptual framework on conducting scoping reviews. We will search five electronic databases (PubMed, CINAHL, Scopus, Embase and Web of Science) and reference lists of publications to identify eligible articles focusing on medical therapy, clinical course or outcomes in adults with HCM and hypertension, between 2011 and 2023. Our search strategy and presentation of results will be guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review guideline. First, two independent reviewers will screen articles, by title and abstract, followed by a full-text screen to identify eligible articles. Relevant data will be extracted and synthesised. ETHICS AND DISSEMINATION: Ethical approval is not required for this review as it is a secondary data collection of published articles and does not involve human subject participation. We will present results of this review at relevant professional conferences and patient-centred educational events. Results will be published in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: https://osf.io/cy8qb/?view_only=98197f4850584e51807ff9b62533a706.

Indexed as

Cardiomyopathy, HypertrophicHypertensionAdultDisease ProgressionHumansResearch DesignScoping Reviews as Topiccardiologyhypertensionhypertrophic cardiomyopathy

Identifiers

PMID37463810
PMCPMC10357759
OpenAlexW4384648992

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.